All Studies | Orsiro US

Clinical Study Overview^a

Filter

Name der Studie	Studientyp	Patienten	Status	1 Endpunkt
BIOFLOW-V	RCT	1,334	Completed, 60-month FU available	TLF at 12 months
BIO-RESORT	RCT	3,514	Completed, 36-month FU available	TVF at 12 months
BIOSTEMI^b	RCT	1,300	Completed, 24-month FU available	TLF at 12 months
BIONYX	RCT	2,488	36-month FU available	TVF at 12 months
BIOSCIENCE	RCT	2,119	Completed, 60-month FU available	TLF at 12 months
Taglieri et al.	Network Meta-Analysis	99,039	Completed	TLF at 12 months and the longest FU available
Madhavan et al.	Meta-Analysis	20,701	Completed	TLF at latest FU reported
BIOFLOW-I	FIM	30	Completed, 12-month FU available	LLL at 9 months
BIOFLOW-II	RCT	452	Completed, 60-month FU available	LLL at 9 months
BIOFLOW-IV	RCT	575	Completed, 60-month FU available	TVF at 12 months
BIOFLOW-VI	RCT	440	48-month FU available	LLL at 9 months
BIOFLOW-VII	Single arm registry	556	Enrollment completed	TLF at 12 months
SMART-CHOICE	RCT	2,993	Completed, Primary endpoint reached	MACCE at 12 months
SORTOUT-IX	RCT	3,151	Completed, 36-month FU available	TLF at 12 months
SORTOUT-VII	RCT	2,525	Completed, 36-month FU available	TLF at 12 months
BIOFLOW-INDIA	Single arm registry	120	Completed	LLL at 9 months
BIOFlow-SV	Single arm registry	1,000	TBA	TLF at 12 months
HATTRICK-OCT	RCT	44	Primary endpoint reached	Strut coverage at 3 months
ORIENT	RCT	372	Primary endpoint reached	LLL at 9 months
ISAR OCT	RCT	75	Completed, Primary endpoint reached	Strut coverage at 6 and 24 months
BIODEGRADE	RCT	3,850	Primary endpoint reached	TLF at 18 months
SCAAR	All comers registry	69,570	24-month FU available	TLR and ST at 12 months